1-4 of 4
Lorenza Bertù
Close
Sort by
Journal Articles

D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study

Clinical Trials & Observations
Gualtiero Palareti, Daniela Poli, Walter Ageno, Cristina Legnani, Emilia Antonucci, Eugenio Bucherini, Sophie Testa, Oriana Paoletti, Antonio Chistolini, Alessandra Serrao, Ida Martinelli, Paolo Bucciarelli, Anna Falanga, Alberto Tosetto, Luca Sarti, Daniela Mastroiacovo, Benilde Cosmi, Adriana Visonà, Rita Carlotta Santoro, Nello Zanatta, Elvira Grandone, Lorenza Bertù, Vittorio Pengo, Lucia Caiano, Paolo Prandoni
Journal: Blood Advances
Blood Adv (2022) 6 (23): 6005–6015.
https://doi.org/10.1182/bloodadvances.2022007973
Published: 2022
Includes: Supplemental data
Journal Articles

A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis

Clinical Trials & Observations
Margherita Maffioli, Barbara Mora, Somedeb Ball, Alessandra Iurlo, Elena Maria Elli, Maria Chiara Finazzi, Nicola Polverelli, Elisa Rumi, Marianna Caramella, Maria Cristina Carraro, Mariella D’Adda, Alfredo Molteni, Cinzia Sissa, Francesca Lunghi, Alessandro Vismara, Marta Ubezio, Anna Guidetti, Sabrina Caberlon, Michela Anghilieri, Rami Komrokji, Daniele Cattaneo, Matteo Giovanni Della Porta, Toni Giorgino, Lorenza Bertù, Marco Brociner, Andrew Kuykendall, Francesco Passamonti
Journal: Blood Advances
Blood Adv (2022) 6 (6): 1855–1864.
https://doi.org/10.1182/bloodadvances.2021006889
Published: 2022
Includes: Supplemental data
Journal Articles

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study

Clinical Trials & Observations
Carlo Visco, Luigi Marcheselli, Roberto Mina, Marianna Sassone, Anna Guidetti, Domenico Penna, Chiara Cattaneo, Valentina Bonuomo, Alessandro Busca, Andrés José María Ferreri, Riccardo Bruna, Luigi Petrucci, Roberto Cairoli, Marco Salvini, Lorenza Bertù, Marco Ladetto, Sofia Pilerci, Antonello Pinto, Safaa Ramadan, Francesco Marchesi, Michele Cavo, Luca Arcaini, Elisa Coviello, Alessandra Romano, Pellegrino Musto, Massimo Massaia, Nicola Fracchiolla, Monia Marchetti, Annamaria Scattolin, Maria Chiara Tisi, Antonio Cuneo, Matteo Della Porta, Livio Trentin, Marco Turrini, Filippo Gherlinzoni, Agostino Tafuri, Sara Galimberti, Monica Bocchia, Valeria Cardinali, Daniela Cilloni, Alessandro Corso, Daniele Armiento, Luigi Rigacci, Elettra Ortu La Barbera, Carlo Gambacorti-Passerini, Giuseppe Visani, Daniele Vallisa, Adriano Venditti, Carmine Selleri, Annarita Conconi, Patrizia Tosi, Francesco Lanza, Anna Candoni, Mauro Krampera, Paolo Corradini, Francesco Passamonti, Francesco Merli, on behalf of the ITA-HEMA-COV investigators
Journal: Blood Advances
Blood Adv (2022) 6 (1): 327–338.
https://doi.org/10.1182/bloodadvances.2021005691
Published: 2022
Includes: Supplemental data
Journal Articles

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients

Clinical Trials & Observations
Margherita Maffioli, Toni Giorgino, Barbara Mora, Alessandra Iurlo, Elena Elli, Maria Chiara Finazzi, Marianna Caramella, Elisa Rumi, Maria Cristina Carraro, Nicola Polverelli, Mariella D’Adda, Simona Malato, Marianna Rossi, Alfredo Molteni, Alessandro Vismara, Cinzia Sissa, Francesco Spina, Michela Anghilieri, Daniele Cattaneo, Rossella Renso, Marta Bellini, Maria Luisa Pioltelli, Chiara Cavalloni, Daniela Barraco, Raffaella Accetta, Lorenza Bertù, Matteo Giovanni Della Porta, Francesco Passamonti
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3196–3200.
https://doi.org/10.1182/bloodadvances.2019000646
Published: 2019
Includes: Supplemental data